Outcome after radical cystectomy in patients with clinical T2 bladder cancer in whom neoadjuvant chemotherapy has failed

BJU International

Volumn 104, Issue 11, 2009, Pages 1646-1649

  Manoharan, Murugesan ^a   Katkoori, Devendar ^a   Kishore, Thekke A ^a   Kava, Bruce ^a   Singal, Rakesh ^a   Soloway, Mark S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder cancer; Clinical T2; Neoadjuvant chemotherapy; Radical cystectomy; Response

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CYSTECTOMY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYSTECTOMY; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 70449362060     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08626.x     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008 58 : 71 96
2. Goldstein MM, Messing EM. Prostate and bladder cancer screening. J Am Coll Surg 1998 186 : 63 74
3. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003 349 : 859 866
4. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003 361 : 1927 1934
5. Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004 171 : 561 569
6. Advanced Bladder Cancer Overview Collaboration. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev 2005 CD005246
7. Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol 2007 177 : 437 443
8. Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 1996 155 : 1903 1906
9. Calabro F, Sternberg CN. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 2009 55 : 348 358
10. McLaughlin S, Shephard J, Wallen E, Maygarden S, Carson CC, Pruthi RS. Comparison of the clinical and pathologic staging in patients undergoing radical cystectomy for bladder cancer. Int Braz J Urol 2007 33 : 25 31
11. Teramukai S, Nishiyama H, Matsui Y, Ogawa O, Fukushima M. Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancer. Clin Cancer Res 2006 12 : 139 143
12. Splinter TA, Scher HI, Denis L et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer - Genitourinary Group. J Urol 1992 147 : 606 608
13. Kassouf W, Grossman HB, Leibovici D et al. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 2009 73 : 147 152
14. Herr HW, Faulkner JR, Grossman HB et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 2004 22 : 2781 2789
15. Bellmunt J, Paz-Ares L, Cuello M et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007 18 : 522 528
16. Takata R, Katagiri T, Kanehira M et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005 11 : 2625 2636
17. Sarkis AS, Bajorin DF, Reuter VE et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995 13 : 1384 1390
18. Edelman MJ, Meyers FJ, Miller TR, Williams SG, Gandour-Edwards R, deVere White RW. Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation. Urology 2000 55 : 521 525
19. Schrier BP, Peters M, Barentsz JO, Witjes JA. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. Eur Urol 2006 49 : 698 703